1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

Sanli Pharmaceuticals

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

1995

Location

Anshun Guizhou China

Primary Industry

Pharmaceuticals

About

Based in Guizhou, China and established in 1995, Sanli Pharmaceuticals is a medicine pharmaceutical companies that focuses on the research, development, manufacture and marketing of Chinese herbal drugs. In April 2020, Sanli Pharmaceuticals raised RMB 299.44 million in an IPO, sellings 40.74 million shares at RMB 7.35 per share on the Shanghai Stock Exchange. The company was awarded as national high-tech enterprise. The products of the company can be categorized into seven categories which are pediatrics, respiratory medicine, cardiovascular and cerebrovascular, bonesetter, rehabilitation, ophthalmology and gastroenterology. Products within include Kai throat spray, Ziheche capsule, Sanqi capsule, Huoxiang Zhengqi capsule, Naoliqing capsule, etc.
Current Investors
Huatai Securities, North Beta Capital, Ysun Investment

Request a demo to show more

Primary Industry
Pharmaceuticals
Sub Industries
Pharmaceuticals
Website
www.gz-sanli.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only

Financials

Fiscal Year Ended
Revenue (USD)
% Revenue Growth (YoY)
Operating Income (USD)
Operating Margin
EBITDA (USD)
% EBITDA Margin
NET Income (USD)
% Net Margin
31 Dec 2017
638,331,037
-
87,529,614
13.7%
110,784,000
17.4%
87,628,189
13.7%
31 Dec 2018
722,346,118
13.2%
99,777,079
13.8%
138,020,900
19.1%
110,480,452
15.3%
31 Dec 2019
31 Dec 2020
31 Dec 2021

Unlock the recent years of financials and more for Sanli Pharmaceuticals.

Request a demo to see more.

Deals

Deals Type
Buyout
PIPE
PIPE
PIPE
Buyout
Deal Status Target (s) Deal Date Investor(s) Seller(s) Deal size (Mn) Enterprise value (Mn) Post-money valuation (Mn) EBITDA multiple (x) Revenue multiple (x) Lead partner (s)
Announced Guiyang dechang xiang pharmaceutcal Co., Ltd. 06 Feb 2022
Completed Sanli Pharmaceuticals 30 Sep 2021
Completed Sanli Pharmaceuticals 30 Jun 2021
Completed Sanli Pharmaceuticals 31 Mar 2021
Completed Guiyang dechang xiang pharmaceutcal Co., Ltd. 22 Jul 2020
Displaying 1-5 of 5

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.